Adial Pharmaceuticals, Inc. announced the appointment of Vinay Shah as the Company’s Chief Financial Officer, effective November 16, 2024. The current CEO, Cary Claiborne expressed excitement about the new addition and thanked the outgoing CFO, Joseph Truluck, for his contributions.
Company Information
Company
Adial Pharmaceuticals
Location
Glen Allen, Virginia, United States
About
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company's ONWARDTM pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company's companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.
Fundz sees it the moment Adial Pharmaceuticals changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Glen AllenBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical